Siemens Healthineers Spring Forum on COVID-19 Testing
Join our hybrid event!
Online at siemens-healthineers.com/eccmid
In-person at ECCMID 2022, Lisbon, Portugal
We pioneer breakthroughs in healthcare. For everyone. Everywhere.
Changing COVID-19 testing demands require clinical laboratories to keep up with an increasing number of patients, samples, and emerging variants. Siemens Healthineers provides the flexibility you want for the clinical results you need with innovative, COVID-19 testing solutions.
While at the Spring Forum on COVID-19 Testing, attend a scientific symposium, meet our experts, and explore our COVID-19 testing portfolio, from a highly sensitive RT-PCR test that can detect Omicron sublineage BA.21 to high throughput or point of care antigen and antibody assays.
Hybrid Event Details
Join Siemens Healthineers at ECCMID 2022 in Lisbon, Portugal
ECCMID 2022
32nd European Congress of Clinical Microbiology & Infectious Diseases
Dates: Saturday, 23 April 2022 – Tuesday, 26 April 2022
Location: Online & Portugal Altice Arena, Lisbon, Portugal, Booth #2-7.2
Hybrid event: Online and in-person
Visit our ECCMID Booth
Join us in Booth #2-7.2
How can your laboratory deliver more impactful results for the detection and management of COVID-19?
Explore a full portfolio of COVID-19 testing solutions from Siemens Healthineers that consistently delivers sensitivity and performance—to get us to what’s next on the path to normalcy.
Attend our ECCMID Symposium
Monday, 25 April 2022 | 12:15-13:15 CET | Hall O
This one-hour integrated symposium will focus on testing for respiratory viruses including SARS-CoV-2 and other seasonal respiratory viruses using molecular methods. The challenging and dynamic nature of this field will be highlighted along with a discussion on how labs are addressing the evolution of testing needs including SARS-CoV-2 variants, seasonal viruses, and potential future outbreaks.
Testing for respiratory viruses: a dynamic field in an evolving environment
Two years of SARS-CoV-2 PCR testing in a large university hospital in Rome: Lessons and findings
Dr. Simona Marchetti, PhD
Department of Laboratory and Infectious Science, "Fondazione Policlinico Universitario A. Gemelli IRCCS"
Rome, Italy
Can diagnostic stewardship and integration of winter surge planning for respiratory virus diagnostics be the basis for coping with the next pandemic?
Pr. Peter Coyle, MD, Senior Consultant
Head of Virology, Hamad General Hospital
Doha, Qatar
Visit our Virtual Platform
Join us at the Spring Forum on COVID-19 Testing
Experience our interactive platform with recorded presentations and whitepapers highlighting our innovative COVID-19 testing solutions, including reflex testing for emerging variants.
April 23-26, 2022
COVID-19 Testing Portfolio
From the lab to the point of care, Siemens Healthineers offers a full portfolio of COVID-19 testing solutions that consistently delivers sensitivity and performance—to get us to what’s next.
Molecular Testing
Gold standard for accurate and early detection of COVID-19 infection in patients.
Automated Real-time PCR RNA Testing
Innovative reflex testing approach for SARS-CoV-2 variant identification.
Assay details
Large-scale Testing and Diagnosis
Clinicians use diagnostic tests to determine if people have current COVID-19 infections, enabling patient management decisions.
High-throughput Lab Antigen Testing
Intended for fast, safe and accurate, high-scale community screening.
Assay details
Satellite Testing
Near-patient testing can be used to identify and isolate infected people more quickly.
Point-of-care Rapid Antigen Testing
Rapid antigen testing can help communities get ahead of the spread.
Self-test details
Management and Monitoring
Management and monitoring are critical in determining the full scope of the disease, combating the pandemic, and rebuilding public confidence.
High-throughput Lab Antibody Testing
Highly accurate for detection and monitoring of immune response through infection and in vaccination.
Point-of-care Antibody Testing
Assay details
Thank you for joining us, see you next year in Copenhagen at ECCMID 2023!
Did this information help you?
FTD R&D in silico report on file, March 2022.
The SARS-CoV-2 molecular and antibody tests have not been FDA-cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. The molecular test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The antibody test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized. for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the. authorization is terminated or revoked sooner. Product availability may vary from country to country and is subject to varying regulatory requirements.
The SARS-CoV-2 Antigen Assay has not been reviewed by the FDA. In the U.S., use of this test is limited to laboratories that are certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high-complexity testing.
For the CLINITEST Rapid COVID-19 Antigen Self-Test, customers may choose between the various country offerings in order to purchase products, but please note products ordered via a specific country page may only be delivered within that specific geography.